EyePoint Pharmaceuticals (EYPT) EBITDA (2010 - 2026)
EyePoint Pharmaceuticals (EYPT) EBITDA from Sep 30, 2010 to Mar 31, 2026. The TTM EyePoint Pharmaceuticals (EYPT) EBITDA is -$279M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
EyePoint Pharmaceuticals (EYPT) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +75.02% |
| 3 Years TTM | +39.69% |
| 5 Years TTM | +50.21% |
| 10 Years TTM | +29.92% |
| All Time TTM | +26.70% |
Annual EBITDA change of EyePoint Pharmaceuticals (EYPT)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$87M | -64.09% |
| 2025 | -$241M | +67.08% |
| 2024 | -$144M | +93.45% |
| 2023 | -$75M | -24.83% |
| 2022 | -$99M | +80.57% |
| 2021 | -$55M | +48.14% |
| 2020 | -$37M | -22.25% |
| 2019 | -$48M | -43.03% |
| 2018 | -$84M | +1349.13% |
| 2017 | -$5.78M | -19.27% |
| 2016 | -$7.16M | +37.96% |
| 2015 | -$5.19M | +27.52% |
| 2014 | -$4.07M | +15.95% |
| 2013 | -$3.51M | +34.48% |
| 2012 | -$2.61M | -85.05% |
| 2011 | -$17M | +549.07% |
| 2010 | -$2.69M | N/A |
Comparison EyePoint Pharmaceuticals (EYPT) five years EBITDA CAGR with competitors
EyePoint Pharmaceuticals (EYPT) five years EBITDA CAGR is 50.19%.